Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. Its lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the c-Kit receptor, inhibiting signaling for mast cells and a maintenance signal for hematopoietic stem cells. KIT inhibition with briquilimab has demonstrated clinical outcomes both as a conditioning agent for stem cell transplant in SCID and Fanconi anemia. Its pipeline also includes KP-104 (vensobafusp alfa), a bifunctional complement inhibitor in clinical development, and KP-701, a preclinical B-cell receptor-targeted therapy.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-10-28	US$0.5388	+3.84%	371,170
26-10-27	US$0.5189	+2.67%	1,324,168
26-10-26	US$0.5054	-0.90%	396,739
26-10-23	US$0.5100	+2.91%	323,719
26-10-22	US$0.4956	-1.73%	72,342

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.5388USD

Average target price

20.00USD

Spread / Average Target

+3,611.95%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Jasper Therapeutics, Inc.

Revisions to estimates

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Jasper Therapeutics, Inc.

Company calendar

Market Closed - Nasdaq 16:00:00 2026-10-28 EDT			5-day change	1st Jan Change
0.5388 ^USD	+3.84%		+6.84%	-70.56%

10-15	Jasper Therapeutics, Inc. Completes Enrollment of Iga Nephropathy Cohort of Phase 2 Basket Study Evaluating Vensobafusp Alfa	CI
09-28	Jasper Therapeutics, Inc. Announces CFO Changes, Effective October 9, 2026	CI

Market Cap	17.93M 16.09M 14.87M 13.47M 25.16M 1.71B 25.47M 178M 70.82M 894M 67.28M 65.86M 2.84B	P/E 2026 *	-	P/E 2027 *	-5.39x
Enterprise Value	17.93M 16.09M 14.87M 13.47M 25.16M 1.71B 25.47M 178M 70.82M 894M 67.28M 65.86M 2.84B	EV / Sales 2026 *	2.99x	EV / Sales 2027 *	-
Free-Float	97.45%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq	JSPR	Delayed
CBOE	JSPR	Real-time

10-15	Jasper Therapeutics, Inc. Completes Enrollment of Iga Nephropathy Cohort of Phase 2 Basket Study Evaluating Vensobafusp Alfa	CI
09-28	Jasper Therapeutics, Inc. Announces CFO Changes, Effective October 9, 2026	CI
09-28	Jasper Therapeutics, Inc. Announces Management Changes, Effective October 9, 2026	CI
09-17	Jasper Therapeutics, Inc.(NasdaqCM:JSPR) added to NASDAQ Composite Index	CI
09-14	Jasper Therapeutics, Inc. Appoints Lisa Pitt, Pharm.D., M.S.J. as Senior Vice President	CI
08-14	Jasper Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-12	Piper Sandler Initiates Jasper Therapeutics With Overweight Rating, $2 Price Target	MT
08-05	Jasper Therapeutics, Inc. announced that it has received $131.996211 million in funding from a group of investors	CI
07-17	Jasper Therapeutics, Inc. Announces Board, Committee and Executive Changes, Effective July 16, 2026	CI
07-16	Jasper Therapeutics Completes Merger With Kira Pharmaceuticals, Shares Fall	MT
07-15	Kira Pharmaceuticals acquired Jasper Therapeutics, Inc. for approximately $200 million in a reverse merger transaction.	CI
07-15	Jasper Therapeutics, Inc. announced that it expects to receive $131.996211 million in funding	CI
06-02	Jasper Therapeutics Initiates Review of Strategic Alternatives to Maximize Shareholder Value	CI

Jasper Therapeutics, Inc. Stock

Stocks

JSPR

US4718712023

Biotechnology & Medical Research

Valuation: Jasper Therapeutics, Inc.

Chart: Jasper Therapeutics, Inc.

Latest news: Jasper Therapeutics, Inc.

Last Transcript: Jasper Therapeutics, Inc.

Analysts' recommendations: Jasper Therapeutics, Inc.

Press Releases: Jasper Therapeutics, Inc.

News in other languages: Jasper Therapeutics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Jasper Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Annual profits - Rate of surprise

08-12	Piper Sandler Initiates Jasper Therapeutics With Overweight Rating, $2 Price Target	MT
05-15	RBC Cuts Price Target on Jasper Therapeutics to $3 From $4, Keeps Sector Perform, Speculative Risk	MT
05-15	TD Cowen Downgrades Jasper Therapeutics to Hold From Buy	MT
03-23	UBS Downgrades Jasper Therapeutics To Neutral From Buy, Cuts Price Target to $1.5 From $25	MT
11-11	RBC Cuts Price Target on Jasper Therapeutics to $4 From $5, Keeps Sector Perform, Speculative Risk	MT

10-07	Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants	AQ
09-15	Jasper Therapeutics Announces Key Regulatory and Clinical Appointments	AQ
09-09	Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference	AQ
08-17	Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update	AQ
08-14	Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update	AQ

25-09-19	USA-Les valeurs à suivre à Wall Street (actualisé)
21-11-15	MÄRKTE USA/Kaum verändert - Zwischen China-Hoffnung und Zinssorgen
21-11-15	MÄRKTE USA/Wall Street dreht leicht ins Minus
21-11-15	MÄRKTE USA/Wall Street mit Vorschusslorbeeren für Biden-Xi-Gipfel
21-11-15	MÄRKTE USA/Wall Street vor Biden-Xi-Gipfel leicht optimistisch

1 day	+3.84%
1 week	+6.84%
Current month	-7.10%
1 month	-13.93%
3 months	-14.88%
6 months	-42.05%
Current year	-70.56%

1 week	0.46	0.55
1 month	0.46	0.65
Current year	0.32	2.07
1 year	0.32	2.48
3 years	0.32	31.01
5 years	0.32	106.9
10 years	0.32	188.8

Manager	Title	Age	Since
Jeet Mahal CEO	Chief Executive Officer	54	2026-01-05
Matthew Ros COO	Chief Operating Officer	59	2026-07-15
Daniel Adelman CTO	Chief Tech/Sci/R&D Officer	68	2023-03-22

Director	Title	Age	Since
Jeet Mahal BRD	Director/Board Member	54	2026-01-05
Judith Shizuru BRD	Director/Board Member	70	2021-09-03
Kurt von Emster BRD	Director/Board Member	59	2021-09-23

Date	Insider	Type	Main position	Quantity	% Market Cap.
7/31/26	Judith Shizuru	Free	Founder	7,500	0.0267%
7/31/26	Patrick Crutcher	Free	Director	7,500	0.0267%
7/31/26	Thomas Wiggans	Free	Chairman	7,500	0.0267%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
JASPER THERAPEUTICS, INC.	+3.84%	+6.84%	-76.97%	-92.20%	17.27M
WUXI APPTEC CO., LTD.	+0.65%	-3.36%	+36.98%	+60.50%	63.48B
ARGENX SE	+1.76%	+1.27%	+11.82%	+81.21%	54.55B
LONZA GROUP AG	-0.94%	+0.99%	+10.45%	+100.19%	53.59B
IQVIA HOLDINGS INC.	+2.76%	+0.87%	+27.92%	+55.07%	44.75B
BEONE MEDICINES AG	+2.00%	-3.39%	+17.83%	+119.04%	41.62B
REVOLUTION MEDICINES, INC.	+1.34%	-2.86%	+224.43%	+914.08%	39.91B
CELLTRION, INC.	+0.64%	-3.95%	+11.15%	+45.57%	32.47B
GENMAB A/S	+29.06%	+47.63%	+107.12%	+92.73%	26.7B
WUXI BIOLOGICS (CAYMAN) INC.	-3.15%	-0.84%	+22.69%	-11.13%	23.36B
Average	+3.80%	+0.73%	+39.34%	+136.51%	38.04B
Weighted average by Cap.	+2.82%	+0.19%	+47.98%	+160.96%

	2026 *	2027 *
Net sales	6M 5.38M 4.98M 4.51M 8.42M 571M 8.52M 59.51M 23.7M 299M 22.52M 22.04M 949M	-
Net income	-	-63.86 -57.29 -52.97 -47.97 -89.63 -6.08K -90.71 -633.32 -252.25 -3.18K -239.63 -234.57 -10.1K
Net Debt	-	-